Vincent Doré1, Santiago Bullich2, Christopher C Rowe3, Pierrick Bourgeat4, Salamata Konate5, Osama Sabri6, Andrew W Stephens2, Henryk Barthel6, Jurgen Fripp4, Colin L Masters7, Ludger Dinkelborg2, Olivier Salvado4, Victor L Villemagne3, Susan De Santi8. 1. Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia. Electronic address: vincent.dore@csiro.au. 2. Life Molecular Imaging, GmbH, Berlin, Germany. 3. Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia. 4. CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia. 5. Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia. 6. Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany. 7. The Florey Institute of Neurosciences and Mental Health, The University of Melbourne, Melbourne, VIC, Australia. 8. Life Molecular Imaging Inc, Boston, MA, USA.
Abstract
INTRODUCTION: 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS: Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy data. RESULTS: Against combined Bielschowsky silver staining and immunohistochemistry histopathological scores, statistical parametric mapping had 96% sensitivity, 96% specificity, and 95% accuracy, whereas magnetic resonance-less CapAIBL standardized uptake value ratioWhole Cerebellum had 94% sensitivity, 96% specificity, and 95% accuracy. Based on the combined histopathological scores, a CL threshold band of 19 ± 7 CL was determined. DISCUSSION: Quantification of 18F-florbetaben positron emission tomography scans using magnetic resonance-based and magnetic resonance-less CapAIBL® approaches showed high agreement, establishing a pathology-based threshold in CL.
INTRODUCTION:18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS: Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy data. RESULTS: Against combined Bielschowsky silver staining and immunohistochemistry histopathological scores, statistical parametric mapping had 96% sensitivity, 96% specificity, and 95% accuracy, whereas magnetic resonance-less CapAIBL standardized uptake value ratioWhole Cerebellum had 94% sensitivity, 96% specificity, and 95% accuracy. Based on the combined histopathological scores, a CL threshold band of 19 ± 7 CL was determined. DISCUSSION: Quantification of 18F-florbetaben positron emission tomography scans using magnetic resonance-based and magnetic resonance-less CapAIBL® approaches showed high agreement, establishing a pathology-based threshold in CL.
Authors: Natasha M Smith; Jeremy N Ford; Arsalan Haghdel; Lidia Glodzik; Yi Li; Debra D'Angelo; Arindam RoyChoudhury; Xiuyuan Wang; Kaj Blennow; Mony J de Leon; Jana Ivanidze Journal: Front Aging Neurosci Date: 2022-04-25 Impact factor: 5.702
Authors: Emily Rosenich; Lisa Bransby; Nawaf Yassi; Jurgen Fripp; Simon M Laws; Ralph N Martins; Christopher Fowler; Stephanie R Rainey-Smith; Christopher C Rowe; Colin L Masters; Paul Maruff; Yen Ying Lim Journal: Neurology Date: 2022-02-15 Impact factor: 11.800
Authors: Soo-Jong Kim; Hongki Ham; Yu Hyun Park; Yeong Sim Choe; Young Ju Kim; Hyemin Jang; Duk L Na; Hee Jin Kim; Seung Hwan Moon; Sang Won Seo Journal: Alzheimers Res Ther Date: 2022-10-20 Impact factor: 8.823
Authors: Vincent Doré; Natasha Krishnadas; Pierrick Bourgeat; Kun Huang; Shenpeng Li; Samantha Burnham; Colin L Masters; Jurgen Fripp; Victor L Villemagne; Christopher C Rowe Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-26 Impact factor: 9.236
Authors: Sanka Amadoru; Vincent Doré; Catriona A McLean; Fairlie Hinton; Claire E Shepherd; Glenda M Halliday; Cristian E Leyton; Paul A Yates; John R Hodges; Colin L Masters; Victor L Villemagne; Christopher C Rowe Journal: Alzheimers Res Ther Date: 2020-03-04 Impact factor: 6.982
Authors: Bernard J Hanseeuw; Vincent Malotaux; Laurence Dricot; Lisa Quenon; Yves Sznajer; Jiri Cerman; John L Woodard; Christopher Buckley; Gill Farrar; Adrian Ivanoiu; Renaud Lhommel Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-29 Impact factor: 9.236
Authors: Laura M van der Kall; Thanh Truong; Samantha C Burnham; Vincent Doré; Rachel S Mulligan; Svetlana Bozinovski; Fiona Lamb; Pierrick Bourgeat; Jurgen Fripp; Stephanie Schultz; Yen Y Lim; Simon M Laws; David Ames; Christopher Fowler; Stephanie R Rainey-Smith; Ralph N Martins; Olivier Salvado; Joanne Robertson; Paul Maruff; Colin L Masters; Victor L Villemagne; Christopher C Rowe Journal: Neurology Date: 2020-11-12 Impact factor: 9.910